Antibody-drug conjugates

The development of antibody-drug conjugates with a specific linker structure addresses the inefficiencies of existing tumor treatments by enhancing delivery and efficacy while minimizing safety risks.

JP7864777B2Active Publication Date: 2026-05-25DAIICHI SANKYO CO LTD
View PDF 11 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
DAIICHI SANKYO CO LTD
Filing Date
2024-07-16
Publication Date
2026-05-25

AI Technical Summary

Technical Problem

Existing antibody-based tumor treatments may not effectively deliver antitumor compounds to tumor cells, leading to insufficient efficacy and potential safety issues, including toxicity and side effects.

Method used

Development of antibody-drug conjugates (ADCs) using a specific linker structure to bind exatecan, an antitumor compound, to antibodies that can target and internalize in tumor cells, enhancing toxicity and ensuring the compound is specifically delivered to tumor cells, thereby reducing the dosage and improving safety.

Benefits of technology

The ADCs achieve enhanced antitumor effects with improved safety by ensuring the antitumor compound is effectively delivered to tumor cells, reducing side effects and increasing therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007864777000151
    Figure 0007864777000151
  • Figure 0007864777000152
    Figure 0007864777000152
  • Figure 0007864777000153
    Figure 0007864777000153
Patent Text Reader

Abstract

To provide an antitumor drug which is excellent in terms of antitumor effect and safety.SOLUTION: There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: L1-L2-LP-NH-(CH2)n1-La-Lb-Lc-, where the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art